Literature DB >> 29294198

Effects of Moisture-Induced Crystallization on the Aerosol Performance of Spray Dried Amorphous Ciprofloxacin Powder Formulations.

Nivedita Shetty1, Lingfei Zeng1, Sharad Mangal1, Haichen Nie2, Matthew R Rowles3, Rui Guo1, Youngwoo Han1, Joon Hyeong Park4, Qi Tony Zhou5.   

Abstract

PURPOSE: This study aims to investigate the influence of different storage humidity conditions on crystallization and aerosol performance of inhalable spray dried amorphous powder formulations (Ciprofloxacin hydrochloride as the model drug).
METHODS: The spray dried samples were stored at 20%, 55% and 75% relative humidity (RH). Crystallinity was monitored by Powder X-ray diffraction (PXRD), and particle morphology was measured by scanning electron microscopy (SEM) and atomic force microscopy (AFM). Aerosol performance was evaluated using a multi-stage liquid impinger (MSLI).
RESULTS: PXRD diffractograms showed the spray dried Ciprofloxacin stored at 20% RH for three weeks were amorphous; whereas those stored at 55% RH and 75% RH started crystallizing after one hour. Fine particle fraction (FPF) of the particles was improved from 28% to 42% after storage at 55% RH for three days. Such improvement was attributed to the crystallization of amorphous powders, which led to increased particle roughness and reduced particulate contact area, as visualized by SEM and quantified by AFM. A linear relationship was observed between degree of crystallinity/crystallite size and FPF (R2 = 0.94 and R2 = 0.96, respectively). However, deterioration in aerosol performance was observed after storage at 75% RH due to formation of inter-particulate liquid/solid bridges, as confirmed by SEM.
CONCLUSIONS: This study provides a fundamental understanding in moisture-induced physical and aerosol instability of the spray dried powder formulations.

Entities:  

Keywords:  aerosol performance; amorphous powder; crystallization; dry powder inhaler; particle surface roughness; spray drying; storage humidity

Mesh:

Substances:

Year:  2018        PMID: 29294198      PMCID: PMC5942560          DOI: 10.1007/s11095-017-2281-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  29 in total

1.  Effect of rise in simulated inspiratory flow rate and carrier particle size on powder emptying from dry powder inhalers.

Authors:  V Chavan; R Dalby
Journal:  AAPS PharmSci       Date:  2000

Review 2.  The inhalers of the future? A review of dry powder devices on the market today.

Authors:  Ian J Smith; Mark Parry-Billings
Journal:  Pulm Pharmacol Ther       Date:  2003       Impact factor: 3.410

3.  Application of partial least-squares (PLS) modeling in quantifying drug crystallinity in amorphous solid dispersions.

Authors:  Alfred C F Rumondor; Lynne S Taylor
Journal:  Int J Pharm       Date:  2010-08-01       Impact factor: 5.875

Review 4.  Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids.

Authors:  Birju Shah; Vasu Kumar Kakumanu; Arvind K Bansal
Journal:  J Pharm Sci       Date:  2006-08       Impact factor: 3.534

5.  Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection.

Authors:  Qi Tony Zhou; Thomas Gengenbach; John A Denman; Heidi H Yu; Jian Li; Hak Kim Chan
Journal:  AAPS J       Date:  2013-10-16       Impact factor: 4.009

Review 6.  Preparation of nanoscale pulmonary drug delivery formulations by spray drying.

Authors:  Adam Bohr; Christian A Ruge; Moritz Beck-Broichsitter
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 7.  Emerging inhalation aerosol devices and strategies: where are we headed?

Authors:  Qi Tony Zhou; Patricia Tang; Sharon Shui Yee Leung; John Gar Yan Chan; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2014-04-13       Impact factor: 15.470

Review 8.  Dry powder inhalation: past, present and future.

Authors:  A H de Boer; P Hagedoorn; M Hoppentocht; F Buttini; F Grasmeijer; H W Frijlink
Journal:  Expert Opin Drug Deliv       Date:  2016-08-30       Impact factor: 6.648

9.  Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.

Authors:  Handoko Adi; Paul M Young; Hak-Kim Chan; Helen Agus; Daniela Traini
Journal:  Eur J Pharm Sci       Date:  2010-04-03       Impact factor: 4.384

10.  Cospray dried antibiotics for dry powder lung delivery.

Authors:  Handoko Adi; Paul M Young; Hak-Kim Chan; Peter Stewart; Helen Agus; Daniela Traini
Journal:  J Pharm Sci       Date:  2008-08       Impact factor: 3.534

View more
  10 in total

1.  Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation.

Authors:  Sharad Mangal; Rongkun Xu; Heejun Park; Dmitry Zemlyanov; Nivedita Shetty; Yu-Wei Lin; David Morton; Hak-Kim Chan; Jian Li; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-11-07       Impact factor: 4.200

2.  Formulation and Manufacturing of Solid Dosage Forms.

Authors:  Qi Tony Zhou; Tonglei Li
Journal:  Pharm Res       Date:  2018-11-27       Impact factor: 4.200

3.  Simultaneous Particle Size Reduction and Homogeneous Mixing to Produce Combinational Powder Formulations for Inhalation by the Single-Step Co-Jet Milling.

Authors:  Junhong Ling; Sharad Mangal; Heejun Park; Shaoning Wang; Alex Cavallaro; Qi Tony Zhou
Journal:  J Pharm Sci       Date:  2019-05-18       Impact factor: 3.534

4.  Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.

Authors:  Nivedita Shetty; Patricia Ahn; Heejun Park; Sonal Bhujbal; Dmitry Zemlyanov; Alex Cavallaro; Sharad Mangal; Jian Li; Qi Tony Zhou
Journal:  Mol Pharm       Date:  2018-08-03       Impact factor: 4.939

5.  Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.

Authors:  Nivedita Shetty; Heejun Park; Dmitry Zemlyanov; Sharad Mangal; Sonal Bhujbal; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2018-04-18       Impact factor: 5.875

6.  Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2019-08-06       Impact factor: 5.571

Review 7.  Physical stability of dry powder inhaler formulations.

Authors:  Nivedita Shetty; David Cipolla; Heejun Park; Qi Tony Zhou
Journal:  Expert Opin Drug Deliv       Date:  2019-12-13       Impact factor: 6.648

8.  Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa.

Authors:  Shihui Yu; Xiaohui Pu; Maizbha Uddin Ahmed; Heidi H Yu; Tarun Tejasvi Mutukuri; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2021-10-06       Impact factor: 5.875

9.  Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation.

Authors:  Sharad Mangal; Heejun Park; Lingfei Zeng; Heidi H Yu; Yu-Wei Lin; Tony Velkov; John A Denman; Dmitry Zemlyanov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2018-07-03       Impact factor: 5.875

10.  Combinations of Freeze-Dried Amorphous Vardenafil Hydrochloride with Saccharides as a Way to Enhance Dissolution Rate and Permeability.

Authors:  Gabriela Wiergowska; Dominika Ludowicz; Kamil Wdowiak; Andrzej Miklaszewski; Kornelia Lewandowska; Judyta Cielecka-Piontek
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.